Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
KLRS Kalaris Therapeutics Inc.
- Stocks
- Healthcare
- NASDAQ: KLRS
Price (delayed)
$3.25
Market cap
$16.39M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$11.73
Enterprise value
-$101.9M
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The
Highlights
Kalaris Therapeutics's debt has plunged by 100% YoY
KLRS's EPS has soared by 72% YoY and by 42% QoQ
The quick ratio has dropped by 74% since the previous quarter
The equity has declined by 22% year-on-year and by 6% since the previous quarter
Key stats
What are the main financial stats of KLRS
Market
Valuations
Earnings
Shares outstanding
5.04M
Market cap
$16.39M
Enterprise value
-$101.9M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.14
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$65.44M
Net income
-$58.77M
EBIT
-$58.77M
EBITDA
-$58.62M
Free cash flow
-$67.71M
Per share
Balance sheet
Liquidity
EPS
-$11.73
EPS diluted
-$11.73
Free cash flow per share
-$13.52
Book value per share
$22.56
Revenue per share
$0
TBVPS
$23.67
Total assets
$118.55M
Total liabilities
$5.24M
Debt
$0
Equity
$113.31M
Working capital
$113.31M
Debt to equity
0
Current ratio
22.63
Quick ratio
22.58
Net debt/EBITDA
2.02
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-45.5%
Return on equity
-49.5%
Return on invested capital
-235.4%
Return on capital employed
-51.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KLRS stock price
How has the Kalaris Therapeutics stock price performed over time
Intraday
-3.85%
1 week
-32.15%
1 month
-55.05%
1 year
-81.16%
YTD
-66.36%
QTD
-59.53%
Financial performance
How have Kalaris Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$65.44M
Net income
-$58.77M
Gross margin
N/A
Net margin
N/A
The net income has soared by 69% year-on-year and by 41% since the previous quarter
The operating income has soared by 67% YoY and by 40% from the previous quarter
Price vs fundamentals
How does KLRS's price correlate with its fundamentals
Growth
What is Kalaris Therapeutics's growth rate over time
Valuation
What is Kalaris Therapeutics stock price valuation
P/E
N/A
P/B
0.14
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
KLRS's EPS has soared by 72% YoY and by 42% QoQ
The price to book (P/B) is 95% less than the 5-year quarterly average of 2.6 and 80% less than the last 4 quarters average of 0.7
The equity has declined by 22% year-on-year and by 6% since the previous quarter
Efficiency
How efficient is Kalaris Therapeutics business performance
KLRS's return on equity has surged by 50% year-on-year and by 37% since the previous quarter
Kalaris Therapeutics's return on invested capital has decreased by 46% YoY and by 19% QoQ
The return on assets rose by 42% year-on-year and by 33% since the previous quarter
Dividends
What is KLRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KLRS.
Financial health
How did Kalaris Therapeutics financials performed over time
KLRS's total liabilities has dropped by 88% year-on-year
The quick ratio has dropped by 74% since the previous quarter
Kalaris Therapeutics's debt is 100% less than its equity
Kalaris Therapeutics's debt has plunged by 100% YoY
KLRS's debt to equity has dropped by 100% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.